Data / Partner portfolio / United Nations / World Health Organization
Research and development agenda defined and research coordinated
Published title: Research and development agenda defined and research coordinated in line with public health priorities
US$ millions unless stated. Haitian fiscal year, October to September. FY2026-27 began October 1, 2026.
Description
The Secretariat will support countries to: increase the integration and coordination among centralized data repositories to share information on research and development pipelines, clinical trials data and health research system indicators globally; enhance national and regional research and development capacity to develop priority, essential health products and utilize target product profiles in the development of new products to address public health needs; rapidly approve, introduce and roll out newly developed paediatric formulations, including support to strengthen post-marketing surveillance and pharmacovigilance specific to the paediatric; and establish an mRNA research and developmentnetwork and convene scientific experts among participating countries to ensure intercountry and inter-region sharing ofscientific expertise and develop long-term capacity-building plan for health products research and development. In producing technical
more
products on norms/standard, data and research, the Secretariat will: create effective cross-organizational mechanisms for research and development, including by establishing research and development networks; develop a joint scientific advice procedure, whereby product developers may approach the Secretariat for advice on prequalification in order to enhance the accelerated development of products that meet the criteria for innovation and likely public health value; update the global priority lists of antimicrobial-resistant bacteria pathogens of public importance; and provide regular reviews and assessments of the development pipeline for treatments and vaccines in order to encourage continued investment in new strategies to promote the development of innovative antibacterial treatments and antifungal treatments and diagnostics.
- Sector
- Health
- Stage
- Closed since December 31, 2025
- Start
- January 1, 2024
- Closing
- December 31, 2025
- Effectiveness
- Not reported
- Departments
- Ouest
- Last transaction
- January 1, 2024
- IATI identifier
Life cycle4 stages, 5 dates
Stage history
| Stage | From |
|---|---|
| Approved | January 1, 2024 |
| Under way | January 1, 2024 |
| Closing | December 31, 2025 |
| Closed | December 31, 2025 |
Dated events
| Event | Date | Source |
|---|---|---|
| Actual start | January 1, 2024 | IATI |
| First commitment | January 1, 2024 | Transactions |
| Planned start | January 1, 2024 | IATI |
| Actual end | December 31, 2025 | IATI |
| Closing date | December 31, 2025 | IATI |
Financing
Table 1.Position at the data date by source (stocks), US$ millions
| This pageUS$ millions | Source | |
|---|---|---|
| Commitment | 0.1 | IATI |
| Disbursed | Not reported | |
| Undisbursed | Not reported | |
| Total cost | Not reported |
IATI amounts. Approved: The commitments the partner reports, converted to US$. Disbursed to date: The disbursements (IATI transaction type 3, money paid to another organization) and expenditure (type 4, money the publisher spent itself) the partner reports, converted to US$. Undisbursed: The undisbursed balance the record gives, where the partner reports one, in US$. Amounts by source
Changes to the operationnot reported
- Original closing date
- Not reported
- Closing date extensions
- Not reported
- Restructurings
- Not reported
- Emergency component
- Not reported
New commitments and disbursements by fiscal year
Table 2.New commitments and disbursements by fiscal year (flows), US$ millions
| FY2023-24US$ millions | |
|---|---|
| New commitments | 0.1 |
| Disbursements | Not reported |
| Cumulative disbursements | Not reported |
Records and documents
Transactions1 record, January 1, 2024
Table 3.Transactions, US$ millions
| Date | Measure | AmountUS$ millions | Source | Method |
|---|---|---|---|---|
| January 1, 2024 | Commitment | 0.1 | IATI | IATI commitment (transaction type 2) |
Terms5 of 6 reported
- Finance type
- 110 Standard grant
- Flow type
- 10 Official development assistance
- Aid type
- B03 Contributions to specific-purpose programs and funds managed by implementing partners
- Tied status
- 5 Untied
- Collaboration type
- 4 Multilateral outflows
- Humanitarian
- Not reported
Policy markers2 policy markers
| Policy marker | Significance | Source |
|---|---|---|
| 3.3 End epidemics of AIDS, tuberculosis, malaria and other diseases | Not reported | IATI |
| 3.8 Universal health coverage | Not reported | IATI |
Locations1 department, 1 place named, 1 place with coordinates
| Departments | Ouest |
| Places named by the source | Port-au-Prince |
| Places with coordinates | 1 |
Identifiers1 identifier
| System | Identifier | Source |
|---|---|---|
| IATI identifier | XM-DAC-928-HT-2024-25-01.003.AM01.HTI04 | IATI |
Partner documents
- Budget, open.who.int
Sources
- IATI record (d-portal): terms of use set by the publisher
- Transactions: terms of use set by the publisher
Data as of October 18, 2026
| Source | Read on |
|---|---|
| IATI | October 18, 2026 |
Cite this page
HaitiDocs. Research and development agenda defined and research coordinated. Partner portfolio, data as of October 18, 2026. https://www.haitidocs.org/portfolio/projects/IATI%3AXM-DAC-928-HT-2024-25-01.003.AM01.HTI04